Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
暂无分享，去创建一个
T. Burns | R. Heist | Y. Murciano-Goroff | A. Balar | A. Patnaik | Ji-Youn Han | D. Deming | T. Koyama | A. Hollebecque | P. Cassier | A. Spira | J. Call | Melinda D Willard | S. Callies | Sae-Won Han | M. Nagasaka | Shiyao Liu | Y. Kuboki | J. Sabari | W. Iams | G. Durm | N. Ammakkanavar | T. Shimizu | Rasha Cosman | Quincy Siu-chung Chu